{"DataElement":{"publicId":"2528397","version":"5.2","preferredName":"New Cancer Diagnosis Type","preferredDefinition":"the type of newly diagnosed malignant neoplasm, dysplastic, or proliferative disease during the indicated period.","longName":"NEW_CA_DX_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2013918","version":"1","preferredName":"New Cancer Diagnosis","preferredDefinition":"the diagnosis of a patient's new primary cancer.","longName":"NEW_CA_DX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206435","version":"1","preferredName":"New Malignant Neoplasm","preferredDefinition":"New; having no previous example or precedent or parallel.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C25586:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F516-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177541","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"Diagnosis","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51C6-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2056FBC-6436-69BA-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2528391","version":"1","preferredName":"Cancer Diagnosis Type","preferredDefinition":"The type of cancer that was diagnosed.","longName":"CA_DZ_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Acute Myeloid Leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B547-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Breast Cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"2581276","version":"1","preferredName":"Breast Carcinoma","longName":"2581276","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B55C-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Other Leukemia","valueDescription":"Leukemia","ValueMeaning":{"publicId":"2567354","version":"1","preferredName":"Leukemia","longName":"2567354","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D427-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B568-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Central Nervous System Malignancy","valueDescription":"Malignant Central Nervous System Neoplasm","ValueMeaning":{"publicId":"2581277","version":"1","preferredName":"Malignant Central Nervous System Neoplasm","longName":"2581277","preferredDefinition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Central Nervous System Neoplasm","conceptCode":"C4627","definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B580-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Hodgkin Disease","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B58F-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Lung Cancer","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"2581279","version":"1","preferredName":"Lung Carcinoma","longName":"2581279","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B5A4-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2561514","version":"1","preferredName":"Melanoma","longName":"2561514","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD57-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-05","modifiedBy":"COOPERM","dateModified":"2018-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B5B0-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Sarcoma","valueDescription":"Sarcoma","ValueMeaning":{"publicId":"2574579","version":"1","preferredName":"Sarcoma","longName":"2574579","preferredDefinition":"A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F060-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"REEVESD","dateModified":"2006-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B5BC-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Thyroid Cancer","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"2581280","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"2581280","preferredDefinition":"A carcinoma arising from the thyroid gland.  It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2019ED6E-B5D4-6107-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Clonal Cytogenetic Abnormality Without Leukemia or MDS","valueDescription":"Clonal Cytogenetic Abnormality Without Leukemia or MDS","ValueMeaning":{"publicId":"2581285","version":"1","preferredName":"Clonal Cytogenetic Abnormality Without Leukemia or MDS","longName":"2581285","preferredDefinition":"Clonal Cytogenetic Abnormality Without Leukemia or MDS.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A92-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201C2C6C-F1D9-1050-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Gastrointestinal Malignancy","valueDescription":"Gastrointestinal Malignancy","ValueMeaning":{"publicId":"2581284","version":"1","preferredName":"Gastrointestinal Malignancy","longName":"2581284","preferredDefinition":"Malignant neoplasm of the stomach and intestines.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A91-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201C2C6C-F1EB-1050-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Genitourinary Malignancy","valueDescription":"Genitourinary Malignancy","ValueMeaning":{"publicId":"2581283","version":"1","preferredName":"Genitourinary Malignancy","longName":"2581283","preferredDefinition":"Malignant neoplasms of the genital and urinary organs.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A90-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201C2C6C-F1FD-1050-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Lymphoma or Lymphoproliferative Disease","valueDescription":"Lymphoma or Lymphoproliferative Disease","ValueMeaning":{"publicId":"2581282","version":"1","preferredName":"Lymphoma or Lymphoproliferative Disease","longName":"2581282","preferredDefinition":"Lymphoma (any of various usually malignant tumors that arise in the lymph nodes or in other lymphoid tissue) or Lymphoproliferative (the proliferation of the bone marrow cells that give rise to lymphoid cells, such as lymphocytes and plasma cells, and reticuloendothelial cells, such as macrophages, which engulf foreign particles). ","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201C2C6C-F20F-1050-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Other Skin Malignancy","valueDescription":"Other Skin Malignancy","ValueMeaning":{"publicId":"2581281","version":"1","preferredName":"Other Skin Malignancy","longName":"2581281","preferredDefinition":"Other Skin Malignancy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201C2C6C-F221-1050-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Myelodysplasia (MDS)/Myeloproliferative (MPS) Disorder","valueDescription":"Myelodysplasia (MDS)/Myeloproliferative (MPS) Disorder","ValueMeaning":{"publicId":"2581286","version":"1","preferredName":"Myelodysplasia (MDS)/Myeloproliferative (MPS) Disorder","longName":"2581286","preferredDefinition":"Myelodysplasia (a syndrome characterised by the appearance of atypical cells in the bone marrow) or myeloproliferative disorder (the proliferation of cells of the bone marrow).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A93-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"CAMPBELB","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201AE964-0378-108B-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Other Malignancy","valueDescription":"Other Malignancy","ValueMeaning":{"publicId":"2581287","version":"1","preferredName":"Other Malignancy","longName":"2581287","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A94-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"LUY","dateModified":"2015-02-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"201AE964-038A-108B-E044-0003BA3F9857","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","deletedIndicator":"No"},{"value":"Breast Cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"3589907","version":"1","preferredName":"Breast Carcinoma","longName":"3589907","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9FF059F-8BC9-73AE-E040-BB89AD4367D2","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA0F5066-C230-5EDF-E040-BB89AD43740A","beginDate":"2006-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-19","modifiedBy":"ONEDATA","dateModified":"2012-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2019ED36-9BB0-60A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"KUMMEROA","dateModified":"2012-09-19","changeDescription":"Updated def for PV \"breast carcinoma\".  No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812017","version":"1","longName":"Phase II Lung Cancer","context":"CTEP"},{"publicId":"2811832","version":"1","longName":"Lung","context":"CTEP"},{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"10000607","version":"1","longName":"Sarcoma","context":"CTEP"},{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"},{"publicId":"2811911","version":"1","longName":"Upper GI","context":"CTEP"},{"publicId":"2811912","version":"1","longName":"Head and Neck","context":"CTEP"},{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"},{"publicId":"2811949","version":"1","longName":"Brain","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811955","version":"1","longName":"Follow-up","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811789","version":"1","longName":"Adjuvant Esophageal","context":"CTEP"},{"publicId":"2811790","version":"1","longName":"Adjuvant Gastric","context":"CTEP"},{"publicId":"2811792","version":"1","longName":"Advanced Esophageal","context":"CTEP"},{"publicId":"10000446","version":"1","longName":"Advanced Gastric","context":"CTEP"},{"publicId":"2811810","version":"1","longName":"NSCLC 2nd Line","context":"CTEP"},{"publicId":"10000001","version":"1","longName":"NSCLC Advanced","context":"CTEP"},{"publicId":"2811817","version":"1","longName":"Primary Cervical","context":"CTEP"},{"publicId":"2811818","version":"1","longName":"Primary Endometrial","context":"CTEP"},{"publicId":"2811819","version":"1","longName":"Primary Ovarian","context":"CTEP"},{"publicId":"2811821","version":"1","longName":"SCLC 2nd Line","context":"CTEP"},{"publicId":"2811822","version":"1","longName":"SCLC Extensive","context":"CTEP"},{"publicId":"2811823","version":"1","longName":"SCLC Limited","context":"CTEP"},{"publicId":"2811827","version":"1","longName":"Unresect Pancreatic","context":"CTEP"},{"publicId":"2811829","version":"1","longName":"Resect Pancreatic","context":"CTEP"},{"publicId":"2811884","version":"1","longName":"Adult STS New","context":"CTEP"},{"publicId":"2811885","version":"1","longName":"Adult STS Recurrent","context":"CTEP"},{"publicId":"2811886","version":"1","longName":"Ped STS New","context":"CTEP"},{"publicId":"2811889","version":"1","longName":"Ped STS Recurrent","context":"CTEP"},{"publicId":"2811904","version":"1","longName":"Multiple Myeloma","context":"CTEP"},{"publicId":"2811905","version":"1","longName":"Primary Amyloidosis","context":"CTEP"},{"publicId":"2811906","version":"1","longName":"Waldenstrom Macrogl","context":"CTEP"},{"publicId":"2811914","version":"1","longName":"Adjuvant Breast","context":"CTEP"},{"publicId":"2811915","version":"1","longName":"Adjuvant Colorectal","context":"CTEP"},{"publicId":"2811916","version":"1","longName":"Localized Prostate","context":"CTEP"},{"publicId":"2811917","version":"1","longName":"Advanced Breast","context":"CTEP"},{"publicId":"2811918","version":"1","longName":"Advanced Colorectal","context":"CTEP"},{"publicId":"2811919","version":"1","longName":"Advanced Melanoma","context":"CTEP"},{"publicId":"2811920","version":"1","longName":"Non-local Prostate","context":"CTEP"},{"publicId":"2811927","version":"1","longName":"Local-Reg Melanoma","context":"CTEP"},{"publicId":"10000311","version":"1","longName":"Met/Urothelial","context":"CTEP"},{"publicId":"10000462","version":"1","longName":"Muscle Invasive Blad","context":"CTEP"},{"publicId":"2811931","version":"1","longName":"NSCLC Stage I-III","context":"CTEP"},{"publicId":"2811938","version":"1","longName":"Recurrent Gyn","context":"CTEP"},{"publicId":"10000312","version":"1","longName":"Superficial Bladder","context":"CTEP"},{"publicId":"10000027","version":"1","longName":"Bone Sarcoma New","context":"CTEP"},{"publicId":"10000028","version":"1","longName":"Bone Sarcoma Recur","context":"CTEP"},{"publicId":"10000369","version":"1","longName":"Curative Head/Neck","context":"CTEP"},{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"},{"publicId":"10000614","version":"1","longName":"Palliative Head/Neck","context":"CTEP"},{"publicId":"2812014","version":"1","longName":"Primary Brain Recurr","context":"CTEP"},{"publicId":"2812013","version":"1","longName":"Primary Brain New","context":"CTEP"},{"publicId":"2812015","version":"1","longName":"Metastatic Brain","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811891","version":"1","longName":"Phase II","context":"CTEP"}]}],"AlternateNames":[{"name":"0001214","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0001792","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0002228","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0058379","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0061338","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0062841","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0064885","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"0065179","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060280065179","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060270064885","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060260062841","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060250061338","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060240058379","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060230002228","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060220001792","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060210001214","type":"HISTORICAL_CDE_ID","context":"CTEP"},{"name":"20060200000690","type":"HISTORICAL_CDE_ID","context":"CTEP"}],"ReferenceDocuments":[{"name":"COMMENT_181","type":"COMMENT","description":"Add instruction: myelodysplastic syndrome","url":null,"context":"CTEP"},{"name":"Diagnosis","type":"Preferred Question Text","description":"Diagnosis","url":null,"context":"NHLBI"}],"origin":"Transplant CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"201AE964-0116-108B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"KUMMEROA","dateModified":"2021-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}